These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 34780866)
1. Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy. Krittanawong C; Khawaja M; Rosenson RS; Amos CI; Nambi V; Lavie CJ; Virani SS Curr Probl Cardiol; 2022 Jul; 47(7):101043. PubMed ID: 34780866 [TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
3. A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo. Suchowerska AK; Stokman G; Palmer JT; Coghlan PA; Pieterman EJ; Keijzer N; Lambert G; Chemello K; Jaafar AK; Parmar J; Yan L; Tong Y; Mu L; Princen HMG; Bonnar J; Evison BJ J Lipid Res; 2022 Nov; 63(11):100293. PubMed ID: 36209894 [TBL] [Abstract][Full Text] [Related]
4. Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment. Sliz E; Kettunen J; Holmes MV; Williams CO; Boachie C; Wang Q; Männikkö M; Sebert S; Walters R; Lin K; Millwood IY; Clarke R; Li L; Rankin N; Welsh P; Delles C; Jukema JW; Trompet S; Ford I; Perola M; Salomaa V; Järvelin MR; Chen Z; Lawlor DA; Ala-Korpela M; Danesh J; Davey Smith G; Sattar N; Butterworth A; Würtz P Circulation; 2018 Nov; 138(22):2499-2512. PubMed ID: 30524137 [TBL] [Abstract][Full Text] [Related]
5. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition. Ouyang M; Li C; Hu D; Peng D; Yu B Clin Chim Acta; 2023 Jan; 538():113-123. PubMed ID: 36403664 [TBL] [Abstract][Full Text] [Related]
7. The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors. Blanchard V; Chemello K; Hollstein T; Hong-Fong CC; Schumann F; Grenkowitz T; Nativel B; Coassin S; Croyal M; Kassner U; Lamina C; Steinhagen-Thiessen E; Lambert G Cardiovasc Res; 2022 Jul; 118(9):2103-2111. PubMed ID: 34314498 [TBL] [Abstract][Full Text] [Related]
8. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Mahmood T; Minnier J; Ito MK; Li QH; Koren A; Kam IW; Fazio S; Shapiro MD Eur J Prev Cardiol; 2021 Jul; 28(8):816-822. PubMed ID: 34298554 [TBL] [Abstract][Full Text] [Related]
9. Statins and PCSK9 inhibitors: A new lipid-lowering therapy. Gallego-Colon E; Daum A; Yosefy C Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598 [TBL] [Abstract][Full Text] [Related]
11. Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies. Oleaga C; Shapiro MD; Hay J; Mueller PA; Miles J; Huang C; Friz E; Tavori H; Toth PP; Wójcik C; Warden BA; Purnell JQ; Duell PB; Pamir N; Fazio S J Am Coll Cardiol; 2021 Oct; 78(14):1437-1449. PubMed ID: 34593126 [TBL] [Abstract][Full Text] [Related]
12. PCSK9 Biology and Its Role in Atherothrombosis. Barale C; Melchionda E; Morotti A; Russo I Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931 [TBL] [Abstract][Full Text] [Related]
17. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects]. Pedro-Botet J; Badimón L Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903 [TBL] [Abstract][Full Text] [Related]
18. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
19. PCSK9 targets important for lipid metabolism. Schulz R; Schlüter KD Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216 [TBL] [Abstract][Full Text] [Related]
20. Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke. De Marchis GM; Dittrich TD; Malik R; Zietz AV; Kriemler LF; Ference BA; Dichgans M; Georgakis MK Atherosclerosis; 2022 Nov; 361():41-46. PubMed ID: 36244797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]